ArticleInfection and immunity2001
Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 116 citations in OpenAlex.
- The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children.PloS one · 2016Trial
- Glycyrrhizin alleviatesJournal of thoracic disease · 2026Article
- Systemic Corticosteroids in Pediatric Community-Acquired Pneumonia: Evidence, Clinical Outcomes, and Phenotype-Based Therapeutic Considerations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- Clinical Characteristics and Early Risk Factors for SevereInfection and drug resistance · 2026Article
- A multi-epitope vaccine targetingFrontiers in immunology · 2026Article
- An immunoinformatics-based designed multi-epitope candidate vaccine against Mycoplasma pneumoniae.BMC microbiology · 2025Article
- Article
- Suppressing neutrophil itaconate production attenuates Mycoplasma pneumoniae pneumonia.PLoS pathogens · 2024Article
- Establishment of a Mouse Model ofMicroorganisms · 2024Article
- A comparative study of general and severe mycoplasma pneumoniae pneumonia in children.BMC infectious diseases · 2024Article
- The novel pleuromutilin derivative 22-((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity bothFrontiers in pharmacology · 2024Article
- Analysis of histopathology and changes of major cytokines in the lesions caused by Mycoplasma ovipneumoniae infection.BMC veterinary research · 2023Article
- Global research trends ofFrontiers in pediatrics · 2023Review
- Pinocembrin Relieves Mycoplasma pneumoniae Infection‑Induced Pneumonia in Mice Through the Inhibition of Oxidative Stress and Inflammatory Response.Applied biochemistry and biotechnology · 2022Article
- Metabolism Characteristics ofAllergy, asthma & immunology research · 2022Article
- B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs.NPJ vaccines · 2022Article
- Ethanol Intoxication Impairs Respiratory Function and Bacterial Clearance and Is Associated With Neutrophil Accumulation in the Lung AfterFrontiers in immunology · 2022Article
- Toll-Like Receptor 2 Modulates Pulmonary Inflammation and TNF-α Release Mediated byFrontiers in cellular and infection microbiology · 2022Article
- Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because Mycoplasma pneumoniae is hypothesized to play an important role in reactive airway disease/asthma, a comprehensive murine model of M. pneumoniae lower respiratory infection was established. BALB/c mice were intranasally inoculated once with M. pneumoniae and sacrificed at 0 to 42 days postinoculation. All mice became infected and developed histologic evidence of acute pulmonary inflammation, which cleared by 28 days postinoculation. By contrast, M. pneumoniae persisted in the respiratory tract for the entire 42 days studied. Tumor necrosis factor alpha, gamma interferon, interleukin-6 (IL-6), KC (functional IL-8), MIP-1alpha, and MCP-1/JE concentrations were significantly elevated in bronchoalveolar lavage samples, whereas IL-4 and IL-10 concentrations were not significantly elevated. Pulmonary airflow resistance, as measured by plethysmography, was detected 1 day postinoculation and persisted even after pulmonary inflammation had resolved at day 28. Serum anti-M. pneumoniae immunoglobulin G titers were positive in all mice by 35 days. This mouse model provides a means to investigate the immunopathogenesis of M. pneumoniae infection and its possible role in reactive airway disease/asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.